Parinov V J, Odinec A G, Gilev A P, Dubur G J, Muceniece D H, Ozol J J, Shatz V D, Gavars M P, Vigante B A
Arzneimittelforschung. 1985;35(5):808-13.
2,6-Dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)-1, 4-dihydropyridine (ryodipine, PP-1466) at oral administration in the form of a suspension with Tween (polysorbate) 80 addition is comparatively rapidly absorbed in the gastro-intestinal tract and circulates in blood for a long period of time. PP-1466 practically does not bind to plasma proteins. The drug is mainly excreted via the kidneys and with faeces by 49 and 46% of the dose administered after 96 h, respectively. PP-1466 metabolites are present in rat urine-2,6-dimethyl-4-arylpyridine-3,5-dicarbonic acid derivatives: oxidation product of PP-1466 dihydropyridine cycle into pyridine one, products of partial or complete hydrolysis of ester groups of PP-1466 oxidized form, lactones. There have been performed the synthesis of labelled 14C-PP-1466 as well as counter-synthesis of PP-1466 metabolites. Unchanged PP-1466 is not detected in urine.
2,6-二甲基-3,5-二甲氧基羰基-4-(邻二氟甲氧基苯基)-1,4-二氢吡啶(利奥地平,PP - 1466)以添加吐温(聚山梨酯)80的混悬液形式口服给药时,在胃肠道吸收相对较快,且能在血液中长时间循环。PP - 1466几乎不与血浆蛋白结合。该药物主要经肾脏排泄,给药96小时后,经粪便排泄的药量分别占给药剂量的49%和46%。PP - 1466的代谢产物存在于大鼠尿液中——2,6-二甲基-4-芳基吡啶-3,5-二羧酸衍生物:PP - 1466二氢吡啶环氧化为吡啶环的产物、PP - 1466氧化形式酯基部分或完全水解的产物、内酯。已进行了标记14C - PP - 1466的合成以及PP - 1466代谢产物的反合成。尿液中未检测到未变化的PP - 1466。